|Rapid review complete
|For long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Evaluation Recommended.
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.